These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 35725813)
1. M-CSF as a therapeutic target in BRAF Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813 [TBL] [Abstract][Full Text] [Related]
2. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy. Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666 [TBL] [Abstract][Full Text] [Related]
6. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143 [TBL] [Abstract][Full Text] [Related]
7. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539 [TBL] [Abstract][Full Text] [Related]
8. Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma. Uebel A; Kewitz-Hempel S; Willscher E; Gebhardt K; Sunderkötter C; Gerloff D Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768289 [TBL] [Abstract][Full Text] [Related]
9. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374 [TBL] [Abstract][Full Text] [Related]
10. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells. Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850 [TBL] [Abstract][Full Text] [Related]
11. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432 [TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2. Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318 [TBL] [Abstract][Full Text] [Related]
14. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Shi H; Moriceau G; Kong X; Koya RC; Nazarian R; Pupo GM; Bacchiocchi A; Dahlman KB; Chmielowski B; Sosman JA; Halaban R; Kefford RF; Long GV; Ribas A; Lo RS Cancer Discov; 2012 May; 2(5):414-24. PubMed ID: 22588879 [TBL] [Abstract][Full Text] [Related]
15. Melanoma cells with acquired resistance to vemurafenib have decreased autophagic flux and display enhanced ability to transfer resistance. Pérez CN; Falcón CR; Mons JD; Orlandi FC; Sangiacomo M; Fernandez-Muñoz JM; Guerrero M; Benito PG; Colombo MI; Zoppino FCM; Alvarez SE Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166801. PubMed ID: 37419396 [TBL] [Abstract][Full Text] [Related]
16. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma. Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534 [TBL] [Abstract][Full Text] [Related]
17. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633 [TBL] [Abstract][Full Text] [Related]
18. Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells. Bokharaie H; Kolch W; Krstic A Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883549 [TBL] [Abstract][Full Text] [Related]
19. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612 [TBL] [Abstract][Full Text] [Related]